Japanese pharma anticipate varying fortunes for next financial year
This article was originally published in Scrip
Japanese pharma companies have begun reporting their annual results, for the full year ending 31 March. While the numbers appear to be in-line with expectations, guidance for the following year has lifted some eyebrows. Meanwhile, Takeda Pharmaceutical – Japan's largest pharmaceutical company – reports its annual results later this week. It has said there will be discrepancies from its previous forecast (announced in February). Profit lines, from operating profit downwards, will be impacted by the US Actos settlement.
You may also be interested in...
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.
Astellas and Pfizer have amended the PROSPER trial protocol in a bid to position Xtandi ahead of Zytiga in the early stage prostate cancer market.